No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal [ 123I]FP-CIT binding in rats

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 3, 2008, Pages 598-604

  Knol, R J J ^a,b   De Bruin, K ^a   Van Eck Smit, B L F ^a   Booij, J ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Graduate School of Neurosciences   (Netherlands)

Author keywords

Acetylcholinesterase inhibitors; Dementia; Dopamine transporters; FP CIT SPECT; Rats

Indexed keywords

ACETYLCHOLINESTERASE; DONEPEZIL; DOPAMINE TRANSPORTER; IODINE 123; METHYLPHENIDATE; RIVASTIGMINE; SODIUM CHLORIDE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CEREBELLUM; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC PROCEDURE; MALE; NONHUMAN; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; CHOLINESTERASE INHIBITORS; CORPUS STRIATUM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; INJECTIONS, INTRAVENOUS; MALE; NORTROPANES; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR;

EID: 43349091054     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0620-1     Document Type: Article

References (20)

1. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-40.
2. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-40.
3. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6.
4. Kilbourn MR, Kemmerer ES, Desmond TJ, Sherman PS, Frey KA. Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain. Exp Neurol 2004;188:387-90.
5. Tsukada H, Nishiyama S, Ohba H, Sato K, Harada N, Kakiuchi T. Cholinergic neuronal modulations affect striatal dopamine transporter activity: PET studies in the conscious monkey brain. Synapse 2001;42:193-5.
6. Taylor JP, Colloby SJ, McKeith IG, Burn DJ, Williams D, Patterson J, et al. Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2007;78:1069-71.
7. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Eur J Pharmacol 2000;389:173-9.
8. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. Eur J Pharmacol 2001;415:157-64.
9. Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, et al. Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther 2000;295:51-7.
10. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 1999;380:101-7.
11. Enz A, Gentsch C. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology 2004;47:408-13.
12. Scali C, Casamenti F, Bellucci A, Costagli C, Schmidt B, Pepeu G. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Transm 2002;109:1067-80.
13. Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 2002;22:7264-71.
14. 123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997;27:183-90.
15. Scheffel U, Lever JR, Abraham P, Parham KR, Mathews WB, Kopajtic T, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse 1997;25:345-9.
16. Lazartigues E, Freslon JL, Tellioglu T, Brefel-Courbon C, Pelat M, Tran MA, et al. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat. Eur J Pharmacol 1998;361:61-71.
17. Dronfield S, Egan K, Marsden CA, Green AR. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat. J Psychopharmacol 2000;14:275-9.
18. Matsui K, Mishima M, Nagai Y, Yuzuriha T, Yoshimura T. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug Metab Dispos 1999;27:1406-14.
19. Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D. Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol 1999;373:187-93.
20. Gorentla BK, Vaughan RA. Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation. Neuropharmacology 2005;49:759-68.